Feb 17 (Reuters) - Sigma Pharmaceuticals Ltd (SIP) :
- Advise that underlying ebit is expected to be just over $100 million for fy
- Fy reported ebit is however expected to be broadly in line with last year
- Sigma pharmaceuticals ltd - "remain comfortable with our existing guidance of at least 5% underlying ebit growth for 2017/18 financial year"
- Sigma pharmaceuticals - new guidance for full year compares with previous guidance of 10% underlying ebit growth
- Forums
- ASX - By Stock
- News: SIP Sigma Pharmaceuticals says FY reported EBIT expected to be broadly in line with last year
Feb 17 (Reuters) - Sigma Pharmaceuticals Ltd (SIP) : Advise...
Featured News
Add SIP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online